GNPX

Genprex Inc

NASDAQ: GNPX · HEALTHCARE · BIOTECHNOLOGY

$7.12

-11.33% today

Updated 2026-07-29

Market cap

$3.94M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-111.32

Dividend yield

—

52W range

$7 – $1,210

Volume

0.3M

Market cap

$3.94M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-111.32

Dividend yield

—

52W range

$7 – $1,210

Volume

0.3M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

6.0

Quality

3.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$7.50

+5.34%

12-Month target

$4.25

-40.31%

Intrinsic (DCF)

—

Margin of safety

—

Price chart

Stock snapshot

Strengths

Insufficient data

Risks

- Piotroski 3/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-3.14M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-23.74M	$-30.86M	$-21.11M	$-16.23M	$-4.46M
EPS	—	—	—	—	$-111.32
Free cash flow	$-17.78M	$-24.81M	$-17.15M	$-15.31M	$-3.14M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
GNPX	$3.94M	26	4.3	3.0	5.0	6.0	—	Avoid
LLY	$1.02T	76	10.0	10.0	4.3	6.0	—	Strong Buy
JNJ	$615.36B	57	4.7	8.5	4.3	6.0	—	Buy
ABBV	$447.53B	63	4.0	8.0	4.7	5.0	-78.83%	Buy
UNH	$391.69B	62	7.3	5.5	4.0	6.0	-30.51%	Buy
MRK	$307.25B	50	3.3	8.0	2.7	5.0	-62.28%	Hold

Smart narrative

Genprex Inc trades at $7.12. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score.

Frequently asked questions

What is Genprex Inc's stock price?

Genprex Inc (GNPX) trades at $7.12.

Is Genprex Inc overvalued?

Genprex Inc carries a Smart Value Score of 26/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Genprex Inc (GNPX)?

The 12-month analyst consensus target is $7.50, about 5.3% above the current $7.12. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-160.80%

Beta-0.91

50D MA$13.21

200D MA$62.10

Shares out0.00B

Float0.00B

Short ratio—

Avg volume0.3M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

GNPX vs LLY →GNPX vs JNJ →GNPX vs ABBV →Stock screener →